New biomarker study aims to track Friedreich's ataxia treatments
NCT ID NCT06496451
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 10 adults with Friedreich's ataxia to find a way to measure frataxin mRNA in blood and spinal fluid. The goal was to create a tool that can tell if treatments are working to increase frataxin levels in the brain. Researchers used tiny particles called exosomes to detect the mRNA. This is a first step toward better monitoring of future therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FRIEDREICH ATAXIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Florida
Gainesville, Florida, 32608, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can voice and hearing tests reveal hidden clues to Friedreich's ataxia progression?
- Video games and AI join the fight against a rare movement disorder
- Can a single gene fix a fatal heart condition? a trial aims to find out
- Brain function in Friedreich's ataxia: new clues from genetic testing
- Pregnancy safety of friedreich ataxia drug under scrutiny
- New brain scans could reveal hidden clues in rare nerve disease